Stocks TelegraphStocks Telegraph
Stock Ideas

FATE Company Profile and Key Details

NASDAQ : FATE

Fate Therapeutics

$3.11
0.18+6.14%
At Close 4:00 PM
$3.03
+0.10+3.41%
After-Market 06:30 PM
58.9
BESG ScoreESG Rating
ProfileKey StatsAnalyst RatingsOwnershipRatiosFinancialsDividend & splitsSentimentForecast

Price Chart

Stock Price Today

Fate Therapeutics, Inc. (FATE) stock surged +6.14%, trading at $3.11 on NASDAQ, up from the previous close of $2.93. The stock opened at $2.96, fluctuating between $2.94 and $3.16 in the recent session.

Stock Snapshot

2.93
Prev. Close
362.5M
Market Cap
2.94
Day Low
-2.85
P/E Ratio
-1.09
EPS (TTM)
-1.4
Cash Flow per Share
2.96
Open
116.56M
Number of Shares
3.155
Day High
87.4%
Free Float in %
3.74
Book Value
3.05M
Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing DateAccepted Date

Annual Report (10-k)

Filing DateAccepted Date

Stock Price History Chart

DateOpenHighLowCloseVolume
Jul 09, 20262.973.162.943.113.05M
Jul 08, 20262.923.082.842.931.91M
Jul 07, 20263.003.152.893.022.42M
Jul 06, 20262.933.122.842.993.39M
Jul 02, 20263.023.212.872.924.19M
Jul 01, 20262.663.112.643.025.87M
Jun 30, 20262.422.722.382.708.27M
Jun 29, 20262.172.482.082.425.89M
Jun 26, 20261.882.111.862.1015.31M
Jun 25, 20262.092.151.811.876.68M
Jun 24, 20262.172.352.052.063.81M
Jun 23, 20262.102.322.072.167.85M
Jun 22, 20262.072.232.012.155.7M
Jun 18, 20262.002.141.932.094.12M
Jun 17, 20261.892.041.881.961.66M
Jun 16, 20262.032.031.861.901.86M
Jun 15, 20262.112.151.952.012.85M
Jun 12, 20262.002.161.932.064.7M
Jun 11, 20261.921.991.821.971.74M
Jun 10, 20261.932.021.871.872.04M

Contact Details

San Diego, CA 92131

United States

https://www.fatetherapeutics.com858 875 1800

About Company

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.

Company Information

Employees181
Beta2.52
Sales or Revenue$63.53M
5Y Sales Change%6.654%
Fiscal Year EndsDecember
SectorHealthcare
IndustryBiotechnology

Stock Peers

ARGX
-5.81-0.63%
argenx SE$909.49REGN
5.07+0.76%
Regeneron Pharmaceuticals, Inc.$667.95MDGL
-5.39-0.95%
Madrigal Pharmaceuticals, Inc.$560.01UTHR
-1.86-0.34%
United Therapeutics Corporation$552.48VRTX
-1.93001-0.39%
Vertex Pharmaceuticals Incorporated$496.50KRYS
-4.15999-1.11%
Krystal Biotech, Inc.$371.24PRAX
0.13+0.04%
Praxis Precision Medicines, Inc.$333.12KRTX
0.09+0.03%
Karuna Therapeutics, Inc.$329.83LGND
7.73+2.45%
Ligand Pharmaceuticals Incorporated$322.61ALNY
-10.70999-3.31%
Alnylam Pharmaceuticals, Inc.$312.79

Company Overview

Fate Therapeutics, Inc. (NASDAQ:FATE) closed at $3.11 USD, gaining $0.18 (6.14%) from the previous close of $2.93. The stock is currently within 5% of its 52-week high $0.91 and $3.21. With a market capitalization of about $362.50 million, Fate Therapeutics, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.52). Key stats such as the average daily volume over the past year has been around 3.92 million shares, in line with its 52-week average. Headquartered in San Diego, CA, Fate Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Bahram Valamehr, the company employs approximately 181 people and listed since October 01, 2013. Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies.

Technical Performance

FATE has shown mixed momentum, gaining 2.8% over the past week and -25.17% over the past quarter, though year-to-date performance is up 11.95%. Short-term trend indicators are mixed aligned (SMA20 21.5%, SMA50 34.1%, SMA200 33.46%). The stock’s 14-day RSI is 66.51 (firm momentum), while the ATR of 0.12 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -19.58% below its high and over 135.99% above its low. Average 10-day trading volume of 4.37 million shares is slightly above the 3-month average of 3.93 million, indicating heightened recent market interest.

Dividend & Fair Value

Fate Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.51. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Fate Therapeutics, Inc. generated EPS of -$1.32 over the past year. Five-year average earnings growth is -2.63%. Wall Street analysts project EPS growth of 10.62% annually over the next five years. The latest quarter delivered EPS of -$0.26. The next quarter is forecast at -$0.27. Next year's EPS is expected at -$16.59. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 3 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $7.00 to $2.50. The high target offers 125.08% upside. The low target suggests -19.61% downside. The mean target is $5.70. This offers 83.28% upside. Fate Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 13, 2026, missed forecasts by -13.33%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -29.55% in March 05, 2025.

Shareholding & Insider Activity

Fate Therapeutics, Inc. has 115.33 million shares outstanding. The public float is 100.80 million shares, elevated short interest at 9.24% of float. This equals 9.28 million shares. The short ratio is 6.34 days. Institutional investors hold 80.04% of the float. Insiders own 1.71%. Redmile Group, LLC holds 12.49 million shares, Valamehr Bahram has 635.76 thousand shares and TAHL CINDY has 628.16 thousand shares. Over the past six months, insider transactions show net selling. They sold 70.32 thousand shares across 4 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Fate Therapeutics generated $63.53M in revenue, or $0.65 per share. Gross margin was 71.22%, operating margin -279.56%, and net profit margin -253.30%. Returns are negative, with ROA at -31.79% and ROE at -43.68%.
On valuation metrics, Fate Therapeutics trades at a P/E of -2.84, P/S of 57.21 and P/B of 2.07. The current ratio is 5.85 and quick ratio is 5.85. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 3.97 days. Debt-to-equity is 0.43, supported by a cash flow-to-debt ratio of -1.34.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Fate Therapeutics posted revenue of $63.53M, down slightly from $96.30M in the prior quarter. Gross profit was $45.25M (margin 71.22%). Operating income was - $177.61M (margin -279.6%). Net income was- $160.93M (EPS - $1.64).
The company ended the quarter with $315.18M in cash and short-term investments, a total debt of $103.54M, and net debt of $61.67M. Total assets were $506.22M, with equity of $368.42M. Financials further reflected weakness, with operating cash flow of - $132.26M, free cash flow of - $138.42M, and capital expenditures of - $6.15M.

Frequently Asked Questions

What is the current Fate Therapeutics, Inc. (FATE) stock price?
Fate Therapeutics, Inc. (NASDAQ: FATE) stock price is $3.11 in the last trading session. During the trading session, FATE stock reached the peak price of $3.16 while $2.94 was the lowest point it dropped to. The percentage change in FATE stock occurred in the recent session was 6.14% while the dollar amount for the price change in FATE stock was $0.18.
FATE's industry and sector of operation?
The NASDAQ listed FATE is part of Biotechnology industry that operates in the broader Healthcare sector. Fate Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of FATE?
Dr. Bahram Valamehr Ph.D.
Chief R&D Officer
Ms. Cindy R. Tahl
Gen. Counsel & Corporation Sec.
Mr. Jim Beitel M.B.A.
Senior Vice President of Corporation Devel.
Mr. Edward J. Dulac III
Chief Financial Officer
Dr. Mark Plavsic D.V.M., Ph.D.
Chief Technical Officer
Dr. Sarah Cooley
Senior Vice President of Clinical Translation
Mr. Brian T. Powl M.B.A., M.S.
Chief Commercial Officer
Dr. Jerome Bressi Ph.D.
Senior Vice President of Regulatory & Quality
Mr. J. Scott Wolchko
Founder, Chief Executive Officer, Pres & Director
Dr. Yu-Waye Chu M.D.
Chief Medical Officer
How FATE did perform over past 52-week?
FATE's closing price is 241.76% higher than its 52-week low of $0.91 where as its distance from 52-week high of $3.21 is -3.12%.
How many employees does FATE have?
Number of FATE employees currently stands at 181.
Link for FATE official website?
Official Website of FATE is: https://www.fatetherapeutics.com
How do I contact FATE?
FATE could be contacted at phone 858 875 1800 and can also be accessed through its website. FATE operates from 12278 Scripps Summit Drive, San Diego, CA 92131, United States.
How many shares of FATE are traded daily?
FATE stock volume for the day was 3.05M shares. The average number of FATE shares traded daily for last 3 months was 3.92M.
What is the market cap of FATE currently?
The market value of FATE currently stands at $362.50M with its latest stock price at $3.11 and 116.56M of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

HomeAboutMeet The TeamContact UsPrivacy PolicyNewsletter

Useful Links

ScreenerMarket DataInsider TransactionsUpgrades & Downgrades52 Week Highs & LowsUnusual VolumeDividend CalendarEarnings CalendarStocks Watchlist
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph